Development of a Validated Novel Bead Extraction Method for the Detection of Anti-PEG Antibodies in Human Serum

Overview

Journal Bioanalysis

Specialty Chemistry

Date 2024 Dec 19

PMID 39696894

Authors

William T Williams

Kathryn Lindley

Hong Liao

Lynn Kamen

Michelle Miller

Amanda Hays

Jeffrey Sailstad

Affiliations

Soon will be listed here.

Abstract

Aims: Polyethylene glycol (PEG) is used in many applications including drug development. Due to exposure to environmental products, there is a high prevalence of preexisting anti-PEG antibodies in the global human population. The presence of anti-PEG antibodies is a concern for potentially reducing the efficacy of therapeutics after administration and represents a risk of safety events after exposure to PEGylated drug products. We developed and validated a creative and sensitive method for the detection of anti-PEG antibodies in human serum to support clinical programs for PEGylated drugs.

Methods: In this method, biotin-PEG streptavidin beads were used to extract anti-PEG antibodies from human serum for analysis in an anti-PEG ELISA assay. The same serum sample was analyzed in an anti-drug antibody assay.

Results: The anti-PEG antibody assay was validated with a screening cut point of 1.41 normalized signal, confirmatory cut point of 32.2% inhibition, sensitivity of 7.81 ng/mL and sufficient reproducibility, selectivity, and drug tolerance in accordance with the FDA 2019 Immunogenicity guidance.

Conclusion: This method of removal of anti-PEG antibodies enables the use of a single sample to detect anti-drug and anti-PEG antibodies to support drug development programs.

References

Myler H, Hruska M, Srinivasan S, Cooney E, Kong G, Dodge R . Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients. Bioanalysis. 2015; 7(9):1093-106. DOI: 10.4155/bio.15.36. View

Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein C, Chamberlain P, Devanaryan V . Anti-drug Antibody Validation Testing and Reporting Harmonization. AAPS J. 2021; 24(1):4. PMC: 8816448. DOI: 10.1208/s12248-021-00649-y. View

Kozma G, Shimizu T, Ishida T, Szebeni J . Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020; 154-155:163-175. DOI: 10.1016/j.addr.2020.07.024. View

Yang Q, Jacobs T, McCallen J, Moore D, Huckaby J, Edelstein J . Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population. Anal Chem. 2016; 88(23):11804-11812. PMC: 6512330. DOI: 10.1021/acs.analchem.6b03437. View

Guerrini G, Gioria S, Sauer A, Lucchesi S, Montagnani F, Pastore G . Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration. Int J Mol Sci. 2022; 23(16). PMC: 9408675. DOI: 10.3390/ijms23168838. View

Turecek P, Bossard M, Schoetens F, Ivens I . PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. J Pharm Sci. 2016; 105(2):460-475. DOI: 10.1016/j.xphs.2015.11.015. View

Bivi N, Swearingen C, Shockley T, Sloan J, Pottanat T, Carter Q . Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity. J Immunol Methods. 2020; 486:112856. DOI: 10.1016/j.jim.2020.112856. View

Xue L, Clements-Egan A, Amaravadi L, Birchler M, Gorovits B, Liang M . Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development. AAPS J. 2017; 19(6):1576-1586. DOI: 10.1208/s12248-017-0153-x. View

Kubiak R, Zhang J, Ren P, Yang H, Roskos L . Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments. J Immunol Methods. 2018; 463:105-111. DOI: 10.1016/j.jim.2018.10.001. View

10.

Mima Y, Hashimoto Y, Shimizu T, Kiwada H, Ishida T . Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein. Mol Pharm. 2015; 12(7):2429-35. DOI: 10.1021/acs.molpharmaceut.5b00144. View

11.

Ganson N, Povsic T, Sullenger B, Alexander J, Zelenkofske S, Sailstad J . Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2015; 137(5):1610-1613.e7. PMC: 5819876. DOI: 10.1016/j.jaci.2015.10.034. View

12.

Stone Jr C, Liu Y, Relling M, Krantz M, Pratt A, Abreo A . Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2018; 7(5):1533-1540.e8. PMC: 6706272. DOI: 10.1016/j.jaip.2018.12.003. View

13.

Zhang P, Sun F, Liu S, Jiang S . Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. J Control Release. 2016; 244(Pt B):184-193. PMC: 5747248. DOI: 10.1016/j.jconrel.2016.06.040. View

14.

Ju Y, Lee W, Pilkington E, Kelly H, Li S, Selva K . Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano. 2022; 16(8):11769-11780. DOI: 10.1021/acsnano.2c04543. View

15.

Chen B, Su Y, Chang C, Burnouf P, Chuang K, Chen C . Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Anal Chem. 2016; 88(21):10661-10666. DOI: 10.1021/acs.analchem.6b03109. View

16.

Hong L, Wang Z, Wei X, Shi J, Li C . Antibodies against polyethylene glycol in human blood: A literature review. J Pharmacol Toxicol Methods. 2020; 102:106678. DOI: 10.1016/j.vascn.2020.106678. View

17.

Chen B, Cheng T, Roffler S . Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano. 2021; 15(9):14022-14048. DOI: 10.1021/acsnano.1c05922. View

18.

Cullis P, Hope M . Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther. 2017; 25(7):1467-1475. PMC: 5498813. DOI: 10.1016/j.ymthe.2017.03.013. View

19.

Veronese F, Mero A . The impact of PEGylation on biological therapies. BioDrugs. 2008; 22(5):315-29. DOI: 10.2165/00063030-200822050-00004. View